1.

Record Nr.

UNINA9910908379503321

Autore

Nandave Mukesh

Titolo

Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure : Mechanisms and Clinical Applications: A Machine-Generated Literature Overview / / edited by Mukesh Nandave

Pubbl/distr/stampa

Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2024

ISBN

9789819775682

9789819775675

Edizione

[1st ed. 2024.]

Descrizione fisica

1 online resource (536 pages)

Disciplina

615

Soggetti

Pharmacology

Medicine - Research

Biology - Research

Pharmacovigilance

Medicine

Cardiology

Biomedical Research

Drug Safety and Pharmacovigilance

Clinical Medicine

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Nota di contenuto

Chapter 1_ The History of the Development of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors for the Treatment of Diabetes: from biology to Chemistry -- Chapter 2_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors and mechanism of cardiovascular benefits in type 2 diabetes  -- Chapter 3_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for primary and secondary protection from cardiovascular and renal diseases in Type 2 diabetes -- Chapter 4_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors: Emerging opportunities for the treatment of myocardial infarction -- Chapter 5_ Potential Role of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in the Treatment and Prevention of Diabetic Cardiomyopathy -- Chapter 6_ Contemporary Management, unmet needs, and Therapeutic Potential of



Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in congestive heart failure -- Chapter 7 A comprehensive review of preclinical and clinical information on the cardiovascular advantages of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors -- Chapter 8_ Exploring the current selective drugs of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for the treatment of cardiovascular disease in Type 2 Diabetes -- Chapter 9_ A comprehensive review of Sodium-glucose Cotransporter-2 (SGLT2) inhibitor’s effects on cardiovascular events, mortality, and significant safety outcomes in individuals with type 2 diabetes.

Sommario/riassunto

The auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the editor(s) of this book. The editor(s) of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that these are extractive auto-summaries, which consist of original sentences, but are not representative of its original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here, and that machine-generated books are still at an experimental stage.